Skip to main content

ICCM5 adopts new framework

The Fifth International Conference on Chemicals Management (ICCM5) concluded on 30 September in Bonn, Germany, by adopting “a comprehensive global framework that sets concrete targets and guidelines for key sectors across the entire lifecycle of chemicals”.

The new Global Framework on Chemicals is based around 28 targets and outlines a roadmap for countries and stakeholders to address the lifecycle of chemicals, including products and waste, collaboratively. It calls, among other things, for the:

* Prevention of the illegal trade and trafficking of chemicals and waste

Arkema shares sustainability targets

At its latest Capital Markets Day on 27 September 2023, Arkema revealed its plans to strengthen its decarbonisation initiatives as well as its financial targets. This followed the recent validation of Arkema’s emissions reduction plan by the Science-Based Targets Initiatives.

Orion opens battery centre

Orion has opened its new Battery Innovation Centre at it main innovation hub in Cologne. The facility includes a full array of production, testing and diagnostic equipment. The focus of its work will be to “accelerate Orion’s tailor-made product and process development in close cooperation with customers”, the company said.

ACC criticises ‘regulatory overreach’

The American Chemistry Council (ACC) has launched an initiative called ‘Chemistry Creates, America Competes’. This comes in direct response to what it regards as the Biden administration’s ‘regulatory overreach’ and aims to help the administration and Congress understand the importance of ‘American Chemistry’.

Elementis in war of words with investor

Speciality chemicals company Elementis has come under pressure after an investor, Franklin Mutual Advisers, published an open letter to board chairman John O’Higgins, calling for it to put itself up for sale before its Q3 results on 31 October. Elementis has responded by saying it did not think this to be in shareholders’ best interests.

New investor for Glemark Life Sciences

Subject to regulatory approval, Glenmark Pharma has agreed to sell a 75% stake in its Glenmark Life Sciences (GLS) business unit to its India compatriot, Nirma. Nirma is a conglomerate which mainly makes detergents and cement but which also acquired sterile contact lens solutions maker Stericon Pharma in April. GLS is mainly active in the manufacture of APIs.

“Synergies between Glenmark Pharma and GLS the business have been rapidly disappearing and companies have had divergent pathways,” said chairman Glenn Saldanha.

Subscribe to Current issue